Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 7/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.60 |
| ▸ | NPY4R | P50391 | 9/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.58 |
| ▸ | NPY1R | P25929 | 7/20 | 0.58 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865075 | 0.95 | TFPI (0.60) | TFPINPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30184327 | 0.95 | TFPI (0.60) | TFPINPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30865068 | 0.94 | TFPI (0.58) | TFPINPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30865071 | 0.93 | TFPI (0.61) | TFPINPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30865074 | 0.92 | NPY4R (0.60) | TFPIBACE1BACE2NPY4RNPY5R | |
| SCHEMBL30883259 | 0.92 | TFPI (0.62) | TFPIBACE1BACE2NPY4RNPY5R | |
| SCHEMBL30184205 | 0.91 | OPRM1 (0.61) | TFPINPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31419699 | 0.89 | TFPI (0.71) | TFPIBACE1BACE2 | |
| SCHEMBL31690552 | 0.89 | GLP1R (0.61) | TFPI | |
| SCHEMBL31145953 | 0.89 | TFPI (0.59) | TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230018324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | IAPP, GLP1R, SLC5A1 | TFPI 330/4885BACE1 498/4885BACE2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.